MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

NCT00506077 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Paranoid Schizophrenia

Interventions

DRUG: MK0249
DRUG: Comparator: Placebo (unspecified)

Sponsor

Merck Sharp & Dohme LLC